Performance of newer myeloma staging systems in a contemporary, large patient cohort

Mohyuddin, Ghulam Rehman; Rubinstein, Samuel M.; Kumar, Shaji; Rajkumar, S. Vincent; Fonseca, Rafael; Abdallah, Nadine H.; Calip, Gregory S.; Wang, Xiaoyan; Parrinello, Christina M.; Sborov, Douglas

doi:10.1038/s41408-024-01076-w

Blood Cancer J.

2024

DOI: 10.1038/s41408-024-01076-w

|View full text |Cite

Performance of newer myeloma staging systems in a contemporary, large patient cohort

Ghulam Rehman Mohyuddin,

Samuel M. Rubinstein,

Shaji Kumar

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Preprint1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

High WEE1 expression is independently linked to poor survival in multiple myeloma

Simhal,

Firestone,

et al. 2024

Preprint

View full text Add to dashboard Cite

Current prognostic scores in multiple myeloma (MM) currently rely on disease burden and a limited set of genomic alterations. Some studies have suggested gene expression panels may predict clinical outcomes, but none are presently utilized in clinical practice. We therefore analyzed the MMRF CoMMpass dataset (N=659) and identified a high-risk group (top tertile) and a low-risk group ( bottom tertile) based on WEE1 expression sorted in descending order. The tyrosine kinase WEE1 is a critical cell cycle regulator during the S-phase and G2M-checkpoint . Abnormal WEE1 expression has been implicated in multiple cancers including breast, ovarian, and gastric cancers, but has not until this time been implicated in MM. PFS was significantly different (p <1e-9) between the groups, which was validated in two independent microarray gene expression profiling (GEP) datasets from the Total Therapy 2 (N=341) and 3 (N=214) trials. Our results show WEE1 expression is prognostic independent of known biomarkers, differentiates outcomes associated with known markers, is upregulated independently of its interacting neighbors, and is associated with dysregulated P53 pathways. This suggests that WEE1 expression levels may have clinical utility in prognosticating outcomes in newly diagnosed MM and may support the application of WEE1 inhibitors to MM preclinical models. Determining the causes of abnormal WEE1 expression may uncover novel therapeutic pathways.

show abstract

High WEE1 expression is independently linked to poor survival in multiple myeloma

Simhal,

Firestone,

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Performance of newer myeloma staging systems in a contemporary, large patient cohort

Cited by 1 publication

References 14 publications

High WEE1 expression is independently linked to poor survival in multiple myeloma

High WEE1 expression is independently linked to poor survival in multiple myeloma

Contact Info

Product

Resources

About